Advertisement

Topics

Novo diabetes drug outperforms Lilly rival at Phase 3

04:49 EDT 17 Aug 2017 | Pharmafile

Novo Nordisk has revealed that its diabetes drug semaglutide managed to outperform Eli Lilly’s own treatment dulaglutide (Trulicity) in controlling glucose levels and promoting weight loss in patients with the type 2 form of the disease when combined with metformin.

read more

Original Article: Novo diabetes drug outperforms Lilly rival at Phase 3

NEXT ARTICLE

More From BioPortfolio on "Novo diabetes drug outperforms Lilly rival at Phase 3"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Diabetes
Diabetes is a lifelong condition that causes a person's blood sugar level to become too high. The two main types of diabetes are: type 1 diabetes type 2 diabetes In the UK, diabetes affects approximately 2.9 million people. There are a...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...